دواعي استعمال اكينزيو 300 / 0.5 مجم 1 كبسولات

كبسولة تحتوي نيتوبيتانت 300 مجم وبالونوسيترون 0.5 مجم للوقاية من القيء المصاحب للعلاج الكيماوي.

• بالاشتراك مع ديكساميثازون للوقاية من الغثيان والقيء الحاد والمتأخر المصاحب للعلاج الكيماوي في البالغين.الفئة: AdultsDailyMed (US National Library of Medicine)

• Most common (>=3%): headache, asthenia, dyspepsia, fatigue, constipation and erythema.نشرة دولية لنفس المنتج · DailyMed (US National Library of Medicine)

• None (per US label).نشرة دولية لنفس المنتج · DailyMed (US National Library of Medicine)

• Hypersensitivity reactions including anaphylaxis have been reported (including in patients with prior 5-HT3 antagonist hypersensitivity).نشرة دولية لنفس المنتج · DailyMed (US National Library of Medicine)
• Serotonin syndrome has been reported with 5-HT3 receptor antagonists, mostly with concomitant serotonergic drugs; discontinue and treat if symptoms occur.نشرة دولية لنفس المنتج · DailyMed (US National Library of Medicine)

• CYP3A4 substrates (e.g. dexamethasone, midazolam, some chemotherapy agents)Netupitant is a moderate CYP3A4 inhibitor and its effect can last several days; avoid or reduce the dose of CYP3A4 substrates for about one week (dexamethasone dose is reduced in the label regimen).DailyMed (US National Library of Medicine)
• Strong CYP3A4 inducers (e.g. rifampin)Reduce netupitant/palonosetron exposure; avoid concomitant use.DailyMed (US National Library of Medicine)
• Serotonergic drugs (SSRIs, SNRIs, MAOIs and others)Risk of serotonin syndrome.DailyMed (US National Library of Medicine)

• Limited human data; adverse embryo-fetal effects were seen in rabbits given netupitant.نشرة دولية لنفس المنتج · DailyMed (US National Library of Medicine)
• No data on presence in human milk or effects on the breastfed infant.نشرة دولية لنفس المنتج · DailyMed (US National Library of Medicine)